Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
eye disease
Biotech
Ocuphire to transform into gene therapy biotech via Opus buyout
Ocuphire is acquiring gene therapy developer Opus in an all-stock transaction that will see the commercial-stage company adopt the biotech’s identity.
James Waldron
Oct 23, 2024 5:31am
Hibernating squirrels hold protein that clears cataracts: study
Sep 20, 2024 11:58am
Beacon attracts $170M series B to fund eye disease gene therapy
Jul 3, 2024 5:00am
Innovent's anti-VEGF drug matches Eylea in eye disease trial
Mar 19, 2024 10:36am
MeiraGTx gifts last of gene therapy rights to J&J for $415M
Dec 21, 2023 10:14am
ProQR, Théa ink new pact for eye assets after old one collapsed
Dec 8, 2023 11:01am